These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 6424327

  • 1. [The effect of various factors on the results of chemotherapy in patients with recurrent ovarian serous cystadenocarcinoma].
    Dzhilavian GA, Vinokurov VL.
    Vopr Onkol; 1984; 30(3):16-21. PubMed ID: 6424327
    [Abstract] [Full Text] [Related]

  • 2. Factors influencing ovarian cancer survival after chemotherapy.
    Webb MJ, Malkasian GD, Jorgensen EO.
    Obstet Gynecol; 1974 Oct; 44(4):564-70. PubMed ID: 4413425
    [No Abstract] [Full Text] [Related]

  • 3. [Intratumor chemotherapy of patients with cancer of the ovaries].
    Vinokurov VL, Mitrokhina MV.
    Vopr Onkol; 1983 Oct; 29(8):58-61. PubMed ID: 6310891
    [Abstract] [Full Text] [Related]

  • 4. [Recurrent epithelial ovarian cancer].
    Ding X, Lang J, Shen K.
    Zhonghua Fu Chan Ke Za Zhi; 1999 Jan; 34(1):30-2. PubMed ID: 11263170
    [Abstract] [Full Text] [Related]

  • 5. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG, Gershenson DM, Malpica A, Deavers M.
    Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
    [Abstract] [Full Text] [Related]

  • 6. Chemotherapy of ovarian cancer. New approaches to treatment.
    Smith JP, Rutledge F, Wharton JT.
    Cancer; 1972 Dec; 30(6):1565-71. PubMed ID: 4345098
    [No Abstract] [Full Text] [Related]

  • 7. [Characteristics of the dissemination process in patients with serous cystadenocarcinoma of the ovaries].
    Dzhilavian GA.
    Vopr Onkol; 1984 Dec; 30(8):83-6. PubMed ID: 6485289
    [Abstract] [Full Text] [Related]

  • 8. [The therapeutic value of second-look laparotomy in advanced ovarian carcinoma].
    Schneider J, Martin M, Erasun F, Matia JC, Rodriguez-Escudero FJ.
    Zentralbl Gynakol; 1988 Dec; 110(22):1443-8. PubMed ID: 3223119
    [Abstract] [Full Text] [Related]

  • 9. [Efficacy of mono- and polychemotherapy in patients with advanced ovarian cancer].
    Khasanova DT, Kotova DG.
    Vopr Onkol; 1984 Dec; 30(3):67-71. PubMed ID: 6369776
    [Abstract] [Full Text] [Related]

  • 10. High-dose melphalan-based chemotherapy and autologous stem cell transplantation after second look laparotomy in patients with chemosensitive advanced ovarian carcinoma: long-term results.
    Bertucci F, Viens P, Delpero JR, Bardou VJ, Faucher C, Houvenaeghel G, Maraninchi D.
    Bone Marrow Transplant; 2000 Jul; 26(1):61-7. PubMed ID: 10918406
    [Abstract] [Full Text] [Related]

  • 11. [Chemotherapy of patients with recurring malignant tumors of the ovaries].
    Kotova DG, Vinokurov VL.
    Vopr Onkol; 1975 Jul; 21(4):19-23. PubMed ID: 812259
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Metastatic ovarian cancer.
    Smith JP, Rutledge FN.
    Clin Obstet Gynecol; 1973 Jun; 16(2):286-97. PubMed ID: 4351522
    [No Abstract] [Full Text] [Related]

  • 14. Chemotherapy in the treatment of cancer of the ovary.
    Smith JP, Rutledge F.
    Am J Obstet Gynecol; 1970 Jul 01; 107(5):691-703. PubMed ID: 4316665
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Therapeutic, clinical and histological factors related to the survival of patients with advanced ovarian carcinoma.
    Kauppila A, Kivinen S, Mäkilä UM, Järvinen PA.
    Ann Chir Gynaecol; 1981 Jul 01; 70(3):91-5. PubMed ID: 7325582
    [Abstract] [Full Text] [Related]

  • 17. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S, Yeap B, Vogl S, Carbone P.
    Cancer; 1996 Feb 15; 77(4):733-42. PubMed ID: 8616766
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Factors influencing the prognosis of ovarian cystadenocarcinomas.
    Nieminen U, Purola E.
    Prog Clin Cancer; 1973 Feb 15; 5():237-47. PubMed ID: 4692474
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.